FILTER
FILTERED INTERVIEW RESULTS
Ikunori Sakai
CEO, MCAP (MITSUI CHEMICALS ASIA PACIFIC)
Mitsui Chemicals Asia Pacific explains how it is diversifying products and expanding markets.
Laurent Nataf
CEO & PRESIDENT ASIA PACIFIC, AZELIS
Azelis is developing Singapore as a financial and logistics hub for all activities in the Asia Pacific region.
Roger Marchioni
ASIA DIRECTOR, CHEMICALS AND POLYMERS, BRASKEM
Braskem speaks to GBR about the goals of its Singapore office.
Dirk Lorenz-Meyer
MEMBER OF THE BOARD, BEHN MEYER GROUP
Behn Meyer Group speaks to GBR about its business in Singapore and SE Asia.
Wim Roels
CEO, BOROUGE
Borouge speaks to GBR about trends affecting its polyethylene and polypropylene solutions business.
Janardhanan Ramanujalu
VICE PRESIDENT & REGIONAL HEAD, SABIC SOUTH ASIA & ANZ, SABIC ASIA PACIFIC PTE. LTD
SABIC speaks to GBR about its efforts to recycle plastics and move towards a circular economy.
Lee Pak Sing
ASSISTANT CEO, TRADE, CONNECTIVITY & BUSINESS SERVICES ENTERPRISE SINGAPORE (ESG)
Enterprise Singapore explains why Singapore remains the first choice destination for the chemical business in Southeast Asia.
Kenneth Lim
GENERAL MANAGER AND SITE DIRECTOR, NESTE SINGAPORE
Neste explains how it is expanding its renewable solutions’ production capacity in Singapore and its innovations in recycling waste.
Peter Wheeler
GENERAL MANAGER OPERATIONS (APAC), BUCKMAN
Buckman speaks to GBR of sustainable and connected chemistry.
Dr. Peter Nagler
CHIEF INNOVATION OFFICER, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) & EXECUTIVE DIRECTOR, A*STAR’S INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES (ICES)
A*STAR and ICES discuss how they are using science to forward the circular economy and find sustainable solutions for Singapore and the world at large.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
